Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: 0.00 (0.00%)
Spread: 0.10 (16.667%)
Open: 0.65
High: 0.65
Low: 0.65
Prev. Close: 0.65
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Centamin Falls After Gold Production Drops

Mon, 09th Jul 2018 10:08

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Just Eat, up 2.4%. RBC Capital raised the online takeaway platform to its Top Pick list.BHP Billiton, up 1.8%. Shares in the Anglo-Australian miner were higher after Reuters reported on Friday that oil major BP is in the lead to acquire the US onshore shale oil and gas assets from BHP after submitting an offer over USD10 billion. BP was down 1.0%.----------FTSE 100 - LOSERS----------Hargreaves Lansdown, down 0.9%. JPMorgan downgraded the funds supermarket to Underweight from Neutral. ----------FTSE 250 - WINNERS----------Stobart Group, up 4.8%. The support services firm said on Saturday that its former chief executive had been re-elected and then immediately dismissed. A majority of shareholders, 51%, voted Andrew Tinkler back onto the board at the company's annual general meeting on Friday, the results of which were delayed until Saturday evening. Tinkler's re-election and his subsequent dismissal were announced within Stobart's Saturday AGM results. In its Saturday statement, Stobart noted that Tinkler's election was passed by the required majority but justified its decision to remove him from the board once again. Tinkler stepped down as chief executive last year but remained on the board. He was removed altogether after accusations of "subverting the company for his own interests" and attempting to cash GBP30 million worth of shares, the Daily Mail said.TalkTalk Telecom Group, up 3.5%. JPMorgan raised the home phone and broadband provider to Neutral from Underweight. ----------FTSE 250 - LOSERS----------Centamin, down 7.5%. The gold miner said second quarter gold production from its Sukari mine in Egypt dropped 25% as underground grades fell below forecast. For the three months to June 30, the miner produced 92,803 ounces of gold compared to 124,641 in the comparative year ago period. In the six months to June 30, production fell 7% to 217,099 ounces form 233,828 ounces year-on-year. In May, the company revised its annual production guidance of between 505,000 and 515,000 ounces at a cash cost of production of USD625 to USD640 per ounce produced and an all-in sustaining cost of USD875 to USD890 per ounce sold. "We have experienced several challenges this year, resulting in the revision of our full year guidance in May," said Chief Executive Officer Andrew Pardey.----------OTHER MAIN MARKET AND AIM - WINNERS----------Legendary Investments, up 17%. The investment company recorded double digit growth in investments and net assets in its recently-ended financial year. In the year to the end of March, the company invested GBP6.2 million versus GBP4.3 million the year before. Net assets saw a 28% increase to GBP6.0 million from GBP4.7 million. During the year, one of Legendary's holdings, Virtualstock Holdings received an investment of GBP4.5 million from European venture capital firm Notion Capital. Legendary holds GBP66 million worth of stake in Virtualstock. In addition, Legendary converted its shares in its Kyrgyz gold asset to shares in Circle Oil Tunisia in December 2017, following Circle Oil Tunisia's acquisition by Dunraven Resources, meaning the the company now holds a 2.0% stake in Dunraven.----------OTHER MAIN MARKET AND AIM - LOSERS----------N4 Pharma, down 52%. The drug reformulation company said that its sildenafil reformulation clinical trial has not met its key target endpoints. The company said that the product formulation will need to be reviewed to assess what changed need to be made to make the reformulated drug viable to N4 Pharma's patent position. "This part of the process of drug reformulation is always going to be a challenge and whilst this preliminary data is clearly disappointing, we will need to see the full set of results expected around the end of August to understand the detailed implications for the formulation," said Chief Executive Officer Nigel Theobald.----------
More News
20 May 2021 19:22

TRADING UPDATES: Gamma tips 2021 revenue jump; Smart Metering progress

TRADING UPDATES: Gamma tips 2021 revenue jump; Smart Metering progress

Read more
17 Mar 2021 16:31

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 Feb 2021 12:34

N4 Pharma losses widen as it works on commercialising Nuvec

(Sharecast News) - Pre-revenue specialist pharmaceuticals company N4 Pharma reported an operating loss of £1.56m in its final results on Wednesday, widening from the £0.95m loss a year earlier.

Read more
24 Feb 2021 10:25

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

Read more
24 Feb 2021 10:03

N4 Pharma Loss Widens As Ramps Up R&D Investment At "Pivotal Time"

N4 Pharma Loss Widens As Ramps Up R&D Investment At "Pivotal Time"

Read more
11 Feb 2021 11:53

N4 Pharma Shares Jump On European Patent Approval For Nuvec

N4 Pharma Shares Jump On European Patent Approval For Nuvec

Read more
11 Feb 2021 11:21

AIM WINNERS & LOSERS: MediaZest Soars As Kicks Off 2021 With Deal Wins

AIM WINNERS & LOSERS: MediaZest Soars As Kicks Off 2021 With Deal Wins

Read more
9 Dec 2020 14:04

IN BRIEF: N4 Pharma Raises GBP2 Million To Fund Development Work

IN BRIEF: N4 Pharma Raises GBP2 Million To Fund Development Work

Read more
4 Dec 2020 10:33

UK WINNERS & LOSERS SUMMARY: Cineworld Falls On Warner Streaming Plans

UK WINNERS & LOSERS SUMMARY: Cineworld Falls On Warner Streaming Plans

Read more
3 Dec 2020 13:39

N4 Pharma shares surge on latest from Nanomerics collaboration

(Sharecast News) - Specialist pharmaceuticals company N4 Pharma updated the market on its ongoing research collaboration agreement with Nanomerics on Thursday.

Read more
3 Dec 2020 10:40

N4 Pharma Shares Soar As Cancer Drug Moves To Phase Two Of Programme

N4 Pharma Shares Soar As Cancer Drug Moves To Phase Two Of Programme

Read more
9 Nov 2020 14:22

N4 Pharma working with Nanomerics on oncology programme

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed Nanomerics to investigate the potential utility of its 'Nuvec' delivery system in cancer therapy.

Read more
9 Nov 2020 14:20

N4 Pharma Plans Nuvec Oncology Treatment Study With UCL's Nanomerics

N4 Pharma Plans Nuvec Oncology Treatment Study With UCL's Nanomerics

Read more
5 Nov 2020 18:07

UK TRADING UPDATE SUMMARY: Zotefoams Hails Record Third Quarter Sales

UK TRADING UPDATE SUMMARY: Zotefoams Hails Record Third Quarter Sales

Read more
17 Sep 2020 14:36

IN BRIEF: N4 Pharma Pretax Loss Widens; Aims To Maximise Nuvec Uses

IN BRIEF: N4 Pharma Pretax Loss Widens; Aims To Maximise Nuvec Uses

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.